In the study by Wainberg et al., exploratory biomarker analyses did not demonstrate significant differences in mPFS or mOS with nivolumab plus chemotherapy when stratified by baseline tumor PD-L1 status < 1% and ≥1% or <5% and ≥5% [54]. This evidence concerns the gene CD274 and neoplasm.